Gemini Bio-Products Announces Partnership with FroggaBio
* FroggaBio to distribute Gemini’s media and sera products across Canada
WEST SACRAMENTO, CA, October 1, 2019 – Gemini Bioproducts, LLC (“Gemini”), a leading supplier of cell culture reagents and a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a New York-based healthcare private equity firm, is pleased to announce an exclusive distribution agreement for Canada with Toronto-based FroggaBio Inc. (“FroggaBio”). Starting today, customers in Canada will be able to purchase Gemini’s current and future products directly from FroggaBio.
Gemini expects the agreement to result in significant growth, after previously serving the Canadian market from its United States operations. Canadian researchers will now have wider access to Gemini’s industry-leading human sera, fetal bovine sera, T-cell media, and other complementary products. FroggaBio’s experienced and technically proficient sales team will bring to Canada the same high level of service that Gemini is reputed for in the United States.
Don O’Neil, Gemini’s Chief Commercial Officer, stated, “We are very excited about this partnership. Canada is a strategically important market with major advances in science and medicine. With FroggaBio, we have found a partner that truly understands our products and will demonstrate them to the right audience.”
FroggaBio CEO Moshe Kapelnikov added, “We have been looking to expand our cell culture offerings for some time. We have admired Gemini for its reputation as a high-quality supplier to many of the top institutions in the United States and internationally for over 30 years. With the new products from Gemini and the burgeoning growth of the cell and gene therapy market, we expect to have many new satisfied customers.”
About Gemini Bio-Products
Founded in 1985, Gemini is a leading manufacturer and supplier of cell culture media, sera, and other reagents to the scientific community across academic research and the biotechnology, cell and gene therapy, and pharma industries. Service offerings include fill & finish and custom media development. Today, a national sales force and an international distribution network serves cell culture laboratories worldwide.
FroggaBio is a Canadian distributor of laboratory products, supply instruments, reagents, and disposables that serves customers within academic and industrial research institutes, biotechnology and pharmaceutical companies, and hospitals. Headquartered in Toronto, Canada, FroggaBio sells a comprehensive line of products in biological, chemical, and diagnostic fields at very competitive prices. They maintain close contact with their customers and stay up to date on scientific developments by attending various local and international scientific conferences.
About BelHealth Investment Partners
BelHealth Investment Partners, based in New York, is a healthcare private equity firm focused on lower middle market companies. BelHealth has a unique combination of investing, executive management and entrepreneurial experience. BelHealth acquires majority positions in entrepreneur-owned companies that it believes would benefit from its extensive operating and private equity investment expertise. The firm invests across three core healthcare segments: Services, Products and Distribution. BelHealth is investing from its current $350 million fund.